福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.63 (2017) >
このアイテムの引用には次の識別子を使用してください:
http://ir.fmu.ac.jp/dspace/handle/123456789/670
|
タイトル: | Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization |
著者: | Fujita, Masashi Abe, Kazumichi Hayashi, Manabu Okai, Ken Takahashi, Atsushi Ohira, Hiromasa |
学内所属: | 消化器内科学講座 |
誌名/書名: | Fukushima Journal of Medical Science |
巻: | 63 |
号: | 3 |
開始ページ: | 165 |
終了ページ: | 171 |
発行日: | 2017年 |
抄録: | Lusutrombopag, a small molecule thrombopoietin receptor agonist, has been approved for the treatment of chronic liver disease-associated thrombocytopenia due to hypersplenism in patients scheduled to undergo elective invasive procedures in Japan. We performed partial splenic embolization (PSE) after administration of lusutrombopag in two patients with thrombocytopenia due to cirrhosis. Case 1 involved a 50-year-old man who developed cirrhosis due to hepatitis B virus (HBV) infection and alcohol consumption. Case 2 involved a 30-year-old woman who developed cirrhosis due to HBV infection only. Lusutrombopag administration led to an increase in platelet count in both patients, and PSE was performed safely. However, in Case 2, the patient developed disseminated intravascular coagulation. Further study with a larger population is required to investigate the indications for and risks of the use of lusutrombopag. |
出版者: | The Fukushima Society of Medical Science |
出版者(異表記): | 福島医学会 |
本文の言語: | eng |
このページのURI: | http://ir.fmu.ac.jp/dspace/handle/123456789/670 |
本文URL: | http://ir.fmu.ac.jp/dspace/bitstream/123456789/670/1/FksmJMedSci_63_p165.pdf |
ISSN: | 0016-2590 2185-4610 |
DOI: | 10.5387/fms.2017-07 |
PubMed番号: | 29142151 |
関連ページ: | https://doi.org/10.5387/fms.2017-07 |
権利情報: | © 2017 The Fukushima Society of Medical Science |
出現コレクション: | Vol.63 (2017)
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|